AMRX FINANCIAL STATEMENTS

Amneal Pharmaceuticals, Inc. Class A Common Stock — balance sheet, income statement and cash flow trends

AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock

🇺🇸 USA · NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue3 B $+7.6%

Gross Profit1.2 B $+13.4%

Operating Income359.3 M $-0.3%

EBITDA626 M $+14.1%

Net Income122.4 M $—

Peer Comparison· Drug Manufacturers - Specialty & Generic

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
AMRX	7.6%	38.7%	20.6%	4.0%
ROVI	-3.4%	63.2%	27.0%	17.8%
BHC	-9.9%	75.9%	60.0%	-13.5%
ECILC	-2.3%	34.3%	14.8%	-3.6%
GENIL	16.3%	23.4%	14.3%	4.0%
MRK	-1.7%	58.5%	28.5%	12.1%
Industry median	7.5%	60.6%	18.2%	4.0%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
AMRX	7.6%	38.7%	20.6%	4.0%
KNSA	56.7%	54.6%	14.3%	9.7%
INDV	10.2%	83.1%	27.3%	19.4%
LNTH	0.6%	60.5%	30.6%	18.0%
LQDA	1,936.7%	91.8%	18.7%	7.7%
HIMS	32.8%	67.6%	1.3%	-0.6%
Industry median	7.5%	60.6%	18.2%	4.0%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Current Liabilities728 M $20%
Long-term Liabilities2.9 B $80%

Key Figures

YoY change

Total Assets3.5 B $+5.2%

Total Liabilities3.6 B $+4.7%

Total Equity-45.4 M $—

Cash & ST Investments197.7 M $+234.0%

Total Debt2.7 B $+4.5%

Net Debt2.5 B $-0.9%

Peer Comparison· Drug Manufacturers - Specialty & Generic

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
AMRX	2.47	-5,938.0%	3.99	-1.3%
ROVI	3.66	17.0%	0.09	72.8%
BHC	1.32	-1,010.0%	3.71	-8.4%
ECILC	1.73	5.9%	-0.10	81.0%
GENIL	1.33	41.0%	1.10	52.6%
MRK	1.51	40.5%	1.38	56.0%
Industry median	2.22	46.3%	1.24	45.7%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
AMRX	2.47	-5,938.0%	3.99	-1.3%
KNSA	3.79	1.5%	-4.26	73.4%
INDV	0.86	-353.5%	0.95	-12.0%
LNTH	2.83	51.6%	0.27	51.7%
LQDA	2.22	170.2%	-0.71	27.0%
HIMS	1.69	253.7%	12.68	19.7%
Industry median	2.22	46.3%	1.24	45.7%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow303.9 M $-1.0%

Capital Expenditures98.6 M $+35.4%

Free Cash Flow205.3 M $-12.3%

Dividends Paid——

Peer Comparison· Drug Manufacturers - Specialty & Generic

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
AMRX	10.0%	6.7%	3.2%	248.3%
ROVI	24.4%	15.5%	8.9%	137.0%
BHC	16.2%	11.3%	4.9%	-119.7%
ECILC	13.9%	16.1%	7.1%	-391.0%
GENIL	6.4%	-6.7%	4.8%	162.4%
MRK	20.0%	11.5%	8.5%	165.6%
Industry median	15.2%	11.6%	2.5%	84.3%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
AMRX	10.0%	6.7%	3.2%	248.3%
KNSA	22.0%	21.8%	0.2%	227.0%
INDV	-8.0%	-14.3%	6.3%	-41.0%
LNTH	26.4%	24.0%	2.3%	146.1%
LQDA	16.7%	14.3%	2.4%	215.1%
HIMS	12.0%	3.2%	8.8%	-2,143.3%
Industry median	15.2%	11.6%	2.5%	84.3%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on AMRX

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 6, 26. This content is for informational purposes only and is not investment advice.